

EHA-TSH Hematology Tutorial

Self-assessment Case – Session 4: Treatment Approaches in R/R PTCL

Speaker: François Lemonnier

Ankara, Türkiye June 29 & 30, 2024



ehaweb.org



• The presenter has no conflicts of interest to disclose as related to companies or products mentioned in this presentation




These materials are provided to you solely as an educational resource for your personal use. Any commercial use or distribution of these materials or any portion thereof is strictly prohibited

Introduction

- 49-year-old male
- Fluctuating cervical and inguinal adenopathy (6 months' duration)
- Rash for 1 month; fever and night sweats (B symptoms)
- Leukocytes: 13.3 × 10⁹/L; Hb: 122 × 10⁹/L; platelets: 269 × 10⁹/L
- Circulating plasma cells: 3%
- LDH: 400 IU/L (normal is < 250 IU/L)
- Gamma globulins: 20.7 g/L
- Presence of a weak CD4⁺ T-cell population that has completely lost surface expression of CD3; partial loss of CD7 and CD26
 - A small proportion express CD10 (~ 10%)
 - There is also a small contingent of circulating plasma cells
- T-cell clone positive; B-cell clone weakly-positive


Serum electrophoresis showing hypergammaglobulinemia



PET–MRI

HEMATOLOGY

Baseline PET–MRI of the patient



PET–MRI, positron emission tomography–magnetic resonance imaging; SUV_{max}, maximum standardized uptake value.

Question 1: What is the next step?

- 1. Start chemotherapy, the T-cell lymphoma diagnosis is obvious
- 2. Bone marrow aspiration to rule out a myeloma
- 3. Lymph node biopsy
- 4. Skin biopsy
- 5. Sequence the circulating T cells




Question 1: What is the next step?

- 1. Start chemotherapy, the T-cell lymphoma diagnosis is obvious
- 2. Bone marrow aspiration to rule out a myeloma
- 3. Lymph node biopsy
- 4. Skin biopsy
- 5. Sequence the circulating T cells



Lymph node biopsy





Question 2: A diagnosis of TFHL is supported by the presence of which of the following?

- 1. TET2 mutation
- 2. *RHOA p.G17V*
- 3. SETD2 mutation
- 4. NPM1 mutation
- 5. t(2;5) translocation



TFHL, T follicular helper cell lymphoma.


Question 2: A diagnosis of TFHL is supported by the presence of which of the following?

- 1. TET2 mutation
- 2. *RHOA p.G17V*
- 3. SETD2 mutation
- 4. NPM1 mutation
- 5. t(2;5) translocation



TFHL, T follicular helper cell lymphoma.

PTCL molecular landscape



de Leval, EHA 2024.



PTCL, peripheral T cell lymphoma

Molecular status of the patient

Tumor

- *TET2 p.R1261C*: 19.6%
- *TET2 p.R1465X*: 26.6%
- *RHOA p.G17V*: 17.4%



Question 3: Which treatment do you recommend?

- 1. CHOEP for 6 cycles plus <u>allogeneic SCT</u>
- 2. Bortezomib plus lenalidomide plus dexamethasone (VRd or RVd)
- 3. CHOEP for 6 cycles plus <u>autologous SCT</u>
- 4. Romidepsin
- 5. Azacitidine



CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone;


Question 3: Which treatment do you recommend?

- 1. CHOEP for 6 cycles plus <u>allogeneic SCT</u>
- 2. Bortezomib plus lenalidomide plus dexamethasone (VRd or RVd)
- 3. CHOEP for 6 cycles plus <u>autologous SCT</u>
- 4. Romidepsin
- 5. Azacitidine



CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone;

ESMO guidelines (2015)



d'Amore F, et al. Ann Oncol. 2015;26 Suppl 5:v108-15.

*

ASSOCIATION

What about frontline autologous SCT?

в

1009

75%

50%

25%

0%

No. at risk

No ASCT 32

ASCT 86

0

— No ASCT


12

25

77

ASCT

Overall survival



Yes


p<0.01

47%

60

3

11



Savage KJ, et al. Blood Adv. 2022;6:5550-5

Brink M, et al. Blood. 2022;140:1009-19

24

21

61

36

15

43

Months from LM 9 months

48

8

32



« TRANSCRIPT»

An open label, controlled, randomized multicentric international study evaluating the benefit of autologous stem cell transplantationafter complete response in frontline setting patients with T cell-lymphoma.



Treatment

- The patient received 4 cycles of CHOEP
 - Achieved partial response
- Patient received 2 cycles of DHAC
- Hematopoietic stem cell collection
- Progressive disease after 2 cycles of DHAC
- A new lymph node biopsy shows the location of the TFHL



DHAC, dexamethasone, cytarabine, carboplatin.

Question 4: Which course of action do you recommend?

- 1. Perform <u>autologous stem cell transplantation</u>
- 2. Perform allogeneic stem cell transplantation
- 3. Include the patient in a clinical trial, if available
- 4. Propose 2 additional cycles of DHAC
- 5. Palliative care, given the poor prognosis of the refractory disease



Question 4: Which course of action do you recommend?

- 1. Perform <u>autologous stem cell transplantation</u>
- 2. Perform <u>allogeneic stem cell transplantation</u>
- 3. Include the patient in a clinical trial, if available
- 4. Propose 2 additional cycles of DHAC
- 5. Palliative care, given the poor prognosis of the refractory disease




ESMO guidelines¹

allogeneic stem-cell transplantation (alloSCT). A proposed treatment algorithm is summarised in Figure 1B. For relapsed/ refractory nodal PTCL other than ALCL, inclusion into clinical trials is highly encouraged. Outside clinical trials, in fit patients, combination chemotherapy regimens such as DHAP (dexamethasone, high-dose cytarabine, cisplatin) or ICE (ifosphamide, etoposide, carboplatin) can be attempted in chemosensitive patients with an available donor, aiming at alloSCT as a potentially curative modality. In unfit patients, monotherapy with gemcitabine or bendamustine are generally well-tolerated, with an ORR of approximately 50% but with modest durations of response [30, 31]. Promising new drugs are under current

UK guidelines²

 All PTCL cases, both untreated and relapsed/refractory, should be considered for a clinical trial wherever possible (GRADE 1B).





1. d'Amore F, et al. Ann Oncol. 2015;26 Suppl 5:v108-15. 2. Fox CP, et al. Br J Haematol. 2022;196:507-52.

Ongoing treatment

- The patient was included in the ORACLE Study, randomized in the oral azacitidine arm
 - Patient received 6 cycles of azacitidine
- PET-CT showed complete response
- Allogeneic SCT was considered



Question 5: Regarding epigenetic-targeted therapies, which of the following statements is true?

- 1. Azacitidine has shown efficacy only in patients harboring a *TET2* mutation
- 2. Romidepsin targets DNA methylation
- 3. Romidepsin targets histone methylation
- 4. Azacitidine is a DNA methyltransferase inhibitor
- 5. Belinotat targets DNA acetylation



Question 5: Regarding epigenetic-targeted therapies, which of the following statements is true?

- 1. Azacitidine has shown efficacy only in patients harboring a *TET2* mutation
- 2. Romidepsin targets DNA methylation
- 3. Romidepsin targets histone methylation
- 4. Azacitidine is a DNA methyltransferase inhibitor
- 5. Belinotat targets DNA acetylation



Question 6: Which of the following is the best course of action regarding allogeneic SCT in patients with R/R PTCL?

- 1. Perform aSCT only in patients with complete response
- 2. Perform aSCT only with a matched related donor
- 3. Perform aSCT only with bone marrow cells
- 4. Perform aSCT only in a fit patient
- 5. Perform aSCT only in patients who have undergone myeloablative conditioning

*aSCT, allogeneic SCT




Question 6: Which of the following is the best course of action regarding allogeneic SCT in patients with R/R PTCL?

- 1. Perform aSCT only in patients with complete response
- 2. Perform aSCT only with a matched related donor
- 3. Perform aSCT only with bone marrow cells
- 4. Perform aSCT only in a fit patient
- 5. Perform aSCT only in patients who have undergone myeloablative conditioning

*aSCT, allogeneic SCT



Donor type does not affect outcome



		os	PFS
At 1 y	CR	79 (76-82)	68 (65-71)
	Partial remission	70 (66-74)	55 (51-59)
	Resistant/untreated	61 (55-65)	45 (39-50)
	Р	<.0001	<.0001
At 3 y	CR	68 (65-71)	57 (53-60)
	Partial remission	59 (54-63)	47 (42-51)
	Resistant/untreated	49 (4455)	36 (31-41)
	Р	<.0001	<0001



haplo, haploidentical; HLA, human leukocyte antigen; MUD, matched unrelated donor; OS, overall survival; PFS, progression free survival; y, year(s). Hamadani M, et al. Blood Adv. 2022;6:920-30.

Donor type does not affect outcome

Source of stem cells	HR	P value
BM	1.00	0.022
Cord blood	1.44 (0.76–2.73)	
PBSC	0.69 (0.41–1.14)	

BM, bone marrow; PBSC, peripheral blood stem cell. Mamez AC, et al. J Hematol Oncol. 2020;13:56.

Ongoing treatment

- Unfortunately, the patient progressed before allogeneic SCT was performed
- Patient was included in a second clinical trial:
 - Patient reached partial response after 4 cycles of the experimental drug
 - Received allogeneic SCT with a matched unrelated donor
- Patient is in sustained complete response after 3 years, with 100% donor chimerism





- Brink M, et al. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study. Blood. 2022;140:1009-19
- d'Amore F, et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v108-15
- Fossard G, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers [published correction appears in Ann Oncol. 2021;32:945]. Ann Oncol. 2018;29:715-23
- Fox CP, et al. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. Br J Haematol. 2022;196:507-22
- Hamadani M, et al. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. Blood Adv. 2022;6:920-930
- Mamez AC, et al. Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). J Hematol Oncol. 2020;13:56
- Savage KJ, et al. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Adv. 2022;6:5550-5

